Member access

4-Traders Homepage  >  Shares  >  Nyse MKT  >  Protalix BioTherapeutics Inc.    PLX   US74365A1016

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse Mkt
03/23/2015 03/24/2015 03/25/2015 03/26/2015 03/27/2015 Date
1.72(c) 1.76(c) 1.73(c) 1.73(c) 1.77(c) Last
89 925 85 889 168 873 87 065 83 449 Volume
-2.27% +2.33% -1.70% 0.00% +2.31% Change
More quotes
Financials ($)
Sales 2013 15,8 M
EBIT 2013 -19,9 M
Net income 2013 -19,0 M
Debt 2013 -
Yield 2013 -
Sales 2014 35,8 M
EBIT 2014 -12,9 M
Net income 2014 -4,70 M
Debt 2014 -
Yield 2014 -
PER 2013 -
PER 2014
Capi. / Sales 2013 10,5x
Capi. / Sales 2014 4,63x
Capitalization 166 M
More Financials
Company
Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins based on ProCellEx plant cell based expression system.It offers Taliglucerase alfa injections under the brand name Elelyso, an enzyme replacement therapy for Gaucher disease.Its drug... 
More about the company
Surperformance© ratings of Protalix BioTherapeutics I
Trading Rating : Investor Rating :
More Ratings
Latest news on PROTALIX BIOTHERAPEUTICS I
03/13 PROTALIX BIOTHERAPEUTICS : Reports Full Year 2014 Financial Results and Provides..
03/12 PROTALIX BIOTHERAPEUTICS : reports 4Q loss
03/12 PROTALIX BIOTHERAPEUTICS : Results of Operations and Financial Condition (form 8..
03/12 Protalix BioTherapeutics Reports Full Year 2014 Financial Results and Provide..
02/12 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
02/12 Protalix BioTherapeutics Presents Additional Positive Phase I/II Interim Clin..
02/11 PROTALIX BIOTHERAPEUTICS : Not Just Braces Anymore. Apple Orthodontix Taps Prost..
02/02 PROTALIX BIOTHERAPEUTICS : Other Events (form 8-K)
More news
Sector news : Biotechnology & Medical Research - NEC
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Biotechnology & Medical Research - NEC
Comments 
Advertisement
Chart PROTALIX BIOTHERAPEUTICS I
Duration : Period :
Protalix BioTherapeutics I Technical Analysis Chart | PLX | US74365A1016 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF